Article

Collaboration: Pfizer, Eyetech in deal for AMD, DME therapy

New York-Pfizer Inc. and Eyetech Pharmaceuticals Inc. will jointly develop and commercialize Eyetech's pegaptanib sodium (Macugen) as a potential treatment for age-related macular degeneration (AMD) and diabetic macular edema (DME).

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: The role of muscle biopsy in heteroplasmy detection
(Image credit: Ophthalmology Times) AGS 2025: Achieving success as an academic ophthalmologist with Thomas V. Johnson III, MD, PhD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
(Image credit: Ophthalmology Times) AGS 2025: Telemedicine and genetics for resource-efficient care with Louis R. Pasquale, MD
Related Content
Cyclosporine A eye drops ease ocular discomfort after cataract surgery
March 13th 2025

Cyclosporine A eye drops ease ocular discomfort after cataract surgery

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Tenpoint Therapeutics Ltd. appoints Carol Kearney as Chief Commercial Officer
March 12th 2025

Tenpoint Therapeutics Ltd. appoints Carol Kearney as Chief Commercial Officer

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

FDA accepts new drug application for low-dose atropine from Sydnexis
March 11th 2025

FDA accepts new drug application for low-dose atropine from Sydnexis

Kodiak Sciences completes enrollment in phase 3 GLOW2 trial of tarcocimab tedromer in patients with diabetic retinopathy
March 11th 2025

Kodiak Sciences completes enrollment in phase 3 GLOW2 trial of tarcocimab tedromer in patients with diabetic retinopathy

© 2025 MJH Life Sciences

All rights reserved.